Gilead Sciences (NASDAQ: GILD) has entered into a collaboration agreement with Cartography Biosciences, a US-based biotechnology company, to discover and develop novel therapies for triple-negative breast cancer (TNBC) and adenocarcinoma. Cartography will leverage its computational and genomics platform to identify and validate target antigens and pairs of antigens in cancer, which are crucial for the development of precise cancer treatments.
Under the terms of the agreement, Cartography will receive an upfront payment of USD 20 million, with the potential for additional milestone payments and sales royalties on targets that Gilead opts to research, develop, and commercialize.- Flcube.com
